Findings seen in children aged 5 to 12 years with low-to-moderate bilateral myopia<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, July 17, 2023 (HealthDay News) — For children aged 5 to 12 years with low-to-moderate bilateral myopia, atropine 0.01 percent eye drops do not slow myopia progression over two years of treatment, according to a study published online July 13 in JAMA Ophthalmology<\/em>.<\/p>\n Michael X. Repka, M.D., from the Wilmer Eye Institute in Baltimore, and colleagues conducted a randomized, placebo-controlled trial involving children aged 5 to 12 years with low-to-moderate bilateral myopia (\u00e2\u0088\u00921.00 to \u00e2\u0088\u00926.00 diopters [D] spherical equivalent refractive error [SER]). A total of 187 children were included in the study: 125 received atropine and 62 received placebo. Children received treatment for 24 months, followed by six months of observation.<\/p>\n The researchers found that the adjusted mean change in SER from baseline was \u00e2\u0088\u00920.82 and \u00e2\u0088\u00920.80 in the atropine and placebo groups, respectively, at the 24-month primary outcome visit (difference, \u00e2\u0088\u00920.02; 95 percent confidence interval, \u00e2\u0088\u00920.19 to +0.15 D). At 30 months, the adjusted difference in mean SER change from baseline was \u00e2\u0088\u00920.04 D (\u00e2\u0088\u00920.25 to +0.17 D). From baseline to 24 months, the adjusted mean changes in axial length were 0.44 and 0.45 in the atropine and placebo groups, respectively (difference, \u00e2\u0088\u00920.002 mm [\u00e2\u0088\u00920.106 to 0.102 mm]). From baseline to 30 months, the adjusted difference in mean axial elongation was +0.009 mm (\u00e2\u0088\u00920.115 to 0.134 mm).<\/p>\n “Overall, clinical trials investigating atropine, 0.01 percent, for myopia control, including the well-done study by Repka et al., indicate that stronger concentrations of atropine should be considered for first-line treatment of myopia progression,” write the authors of an accompanying editorial.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n